FDA rejects Capricor Therapeutics’ Duchenne muscular dystrophy drug
The US Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee has voted that available evidence does not support the effectiveness of Capricor Therapeutics’ Deramiocel for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy (DMD). DMD is a rare and life-threatening disease for… Read More